Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells

At the 50th Annual Meeting of the American Society for Clinical Oncology , University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 , an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells .

http://ift.tt/1pvht1I